T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial
| Autor: | Jebbink, M., De Langen, A. J., Monkhorst, K., Boelens, M. C., Van den Broek, D., Van der Noort, V., De Gooijer, C. J., Van der Wekken, A. J., Hendriks, L., Hashemi, S. M. S., Paats, M. S., Dingemans, A., Smit, E. |
|---|---|
| Přispěvatelé: | Pulmonary medicine, VU University medical center, Obstetrics and gynaecology, CCA - Cancer Treatment and quality of life |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Zdroj: | Journal of Thoracic Oncology, 16(10), S891-S892. International Association for the Study of Lung Cancer Jebbink, M, De Langen, A J, Monkhorst, K, Boelens, M C, Van den Broek, D, Van der Noort, V, De Gooijer, C J, Van der Wekken, A J, Hendriks, L, Hashemi, S M S, Paats, M S, Dingemans, A & Smit, E 2021, ' T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial ', Journal of Thoracic Oncology, vol. 16, no. 10, pp. S891-S892 . |
| ISSN: | 1556-0864 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|